EMMA (Emmaus Life Sciences) Beginning Cash Position: $2.13 Mil (As of Mar. 2026)


What is Emmaus Life Sciences Beginning Cash Position?

Emmaus Life Sciences EMMA -2.80% Beginning Cash Position is $2.13 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Emmaus Life Sciences's Beginning Cash Position for the quarter that ended in Mar. 2026 was $2.13 Mil.

Emmaus Life Sciences's quarterly Beginning Cash Position declined from Sep. 2025 ($0.89 Mil) to Dec. 2025 ($0.29 Mil) but then increased from Dec. 2025 ($0.29 Mil) to Mar. 2026 ($2.13 Mil).

Emmaus Life Sciences's annual Beginning Cash Position increased from Dec. 2023 ($2.02 Mil) to Dec. 2024 ($2.55 Mil) but then declined from Dec. 2024 ($2.55 Mil) to Dec. 2025 ($1.39 Mil).

Emmaus Life Sciences Beginning Cash Position Related Terms

Emmaus Life Sciences Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Beginning Cash Position Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.49 2.28 2.02 2.55 1.39

Emmaus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.39 1.33 0.89 0.29 2.13

Emmaus Life Sciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $2.13 Mil mean?
Emmaus Life Sciences (EMMA) has a Beginning Cash Position of $2.13 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Emmaus Life Sciences and its competitors.
Is Emmaus Life Sciences' Beginning Cash Position too high?
Emmaus Life Sciences' current Beginning Cash Position is $2.13 Mil.
How does Emmaus Life Sciences' Beginning Cash Position compare to PTIX and BZYR?
Emmaus Life Sciences' Beginning Cash Position of $2.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current Beginning Cash Position is $2.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 11% above its estimated fair value. The current Beginning Cash Position is $2.13 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Beginning Cash Position is $2.13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.